Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05052996 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
A Phase 2 study of HIV-1-infection, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 20
- Study locations
NCT05052996 is a Phase 2 study of HIV-1-infection that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 142 participants, below the 349-participant average among 71 other HIV-1-infection trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05052996, a Phase 2 study of HIV-1-infection, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologically suppressed people with HIV (PWH) at Week 24.
Conditions Studied
Interventions
- DRUG B/F/TAF
- DRUG ISL
- DRUG LEN
- DRUG ISL/LEN FDC
Study Locations (20)
California
- Pacific Oaks Medical Group - Beverly Hills
- Ruane Clinical Research Group, Inc - Los Angeles
- Mills Clinical Research - Los Angeles
- Hoag Medical Group - Newport Beach - Newport Beach
- BIOS Clinical Research - Palm Springs
- Optimus Medical Group - San Francisco
Florida
- CAN Community Health Care, Inc. - Fort Lauderdale
- Midway Immunology and Research Center - Ft. Pierce
- JEM Research Institute - Lake Worth
- Schiff Center for Liver Diseases/University of Miami - Miami
- Floridian Clinical Research - Miami Lakes
- Orlando Immunology Center - Orlando
Georgia
- Emory University Hospital Midtown Infectious Disease Clinic - Atlanta
- Atlanta ID Group, PC - Atlanta
- Metro Infectious Disease Consultants - Decatur
- Chatham County Health Department - Savannah
Colorado
- Public Health Institute at Denver Health - Denver
- Vivent Health - Denver
District of Columbia
- Washington Health Institute - Washington D.C.
- The George Washington University Medical Faculty Associates Inc. - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2021-10-05 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05052996
The ClinicalTrials.gov registry entry for NCT05052996 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 349-participant average among 71 other HIV-1-infection trials with a reported enrollment target (59% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 4 interventions - of which B/F/TAF is the first listed.
NCT05052996 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05052996 about?
NCT05052996 is a clinical study titled "Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV". The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologically suppressed people with HIV (PWH) at Week 24.
What is the current status of trial NCT05052996?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2021-10-05. Estimated completion is 2028-03.
What conditions does trial NCT05052996 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT05052996?
The interventions under investigation include: B/F/TAF (DRUG), ISL (DRUG), LEN (DRUG), ISL/LEN FDC (DRUG).
Who is sponsoring clinical trial NCT05052996?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05052996 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
PrEPsmart 2-1-1 Pilot
RECRUITING · Phase 2
-
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.